Stockreport

Marketing applications under review in U.S. and Europe for Vertex's CF combo tezacaftor/ivacaftor, FDA action date February 28, 2018 [Seeking Alpha]

Vertex Pharmaceuticals Incorporated  (VRTX) 
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.vrtx.com
PDF Vertex Pharmaceuticals ( VRTX ) announces that its marketing applications seeking approval for tezacaftor/ivacaftor for cystic fibrosis (CF) patients who have [Read more]